ALK and lung carcinoma: ALK Rearrangements in Lung Cancer: Rearrangements involving the anaplastic lymphoma kinase (ALK) gene in NSCLC are predictive biomarkers for response to ALK inhibitors like crizotinib, alectinib, and brigatinib [404].